Krystal Biotech, Inc. (KRYS)

Nasdaq · Healthcare · Biotechnology
$308.89-2.19%As of 2026-11-22 · USD
Last session low $308.22Last session high $321.24
52-week low $212.0252-week high $382.54
Market cap
$9.15B
Sector
Healthcare
P/E (TTM)
42.0x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)49.9In the neutral range (30 to 70)
MACD (12, 26, 9)-3.87Above its signal line (-5.70); histogram 1.83
Bollinger %B (20, 2)48%Inside the bands (290.70 to 328.85)
SMA 20309.78Price is 0.3% below
SMA 50322.58Price is 4.2% below
SMA 200310.52Price is 0.5% below
ATR (20)3.65% of priceAverage true range per day
52-week position57%In the middle of the 212.02 to 382.54 range

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Insider filings, 90 daysNo purchases and 2 sales (about $18.0M).
Latest fiscal yearEnded 2025-12-31: revenue of $389.13M and an operating margin of 41.5%.

More in Biotechnology